Abstract P062: The CL2A-SN38 linker-payload system conjugated to trastuzumab results in improved cellular cytotoxicity over time relative to T-DM1

连接器 细胞毒性 化学 结合 共轭体系 曲妥珠单抗 内化 抗体-药物偶联物 内体 组合化学 生物物理学 生物化学 单克隆抗体 抗体 癌症 体外 细胞内 细胞 生物 有机化学 遗传学 计算机科学 操作系统 免疫学 聚合物 乳腺癌 数学分析 数学
作者
Hardeep Singh,Jeffrey Victor Leyton
出处
期刊:Molecular Cancer Therapeutics [American Association for Cancer Research]
卷期号:20 (12_Supplement): P062-P062 被引量:3
标识
DOI:10.1158/1535-7163.targ-21-p062
摘要

Abstract Background The approved antibody-drug conjugate (ADC) sacituzumab-govitecan (SG) that exploits the topoisomerase I inhibitor SN38, represents a substantial advance in the ADC field. SN38 is the first payload with low nanomolar cytotoxicity. This deviates from current design principles, which utilize ultracytotoxic payloads. The CL2A linker has a short non-cleavable seven polyethylene glycol segment that enables a higher number of hydrophobic SN38 molecules to be attached to reduced cysteines. CL2A is also designed to permit the release of SN38 in an acidic environment via a pH-sensitive benzyl carbonate bond to SN38’s lactone ring. There is no cathepsin B cleavage site. Key to the performance of SG is the SN38 release half-life of 1-2 days. This also deviates from very stable linker systems that require full ADC internalization and lysosomal processing for payload release. As a result of these novel ADC properties, SG is given in higher and repeated doses, which results in slow release at the tumor site and enhanced uptake by target cancer cells and reduced toxicity on healthy cells due to low potency SN38 alone. Our goal is to further evaluate the CL2A-SN38 system when conjugated to trastuzumab. Material and methods Trastuzumab was conjugated to CL2A-SN38 to reduced cysteines (T-SN38). Monitoring the changes in DAR over time was performed to determine the stability of T-SN38 in PBS at pH values of 7.4, 5.72, and 4.58, to mimic circulating blood, early endosomes, and lysosomes, respectively. Cytotoxicity assays for 72 h on HER2-positive ovarian cancer SKOV3.ip and HER2-negative CHO cells were performed and compared to the approved anti-HER2 ADC trastuzumab-emtansine (T-DM1). Cytotoxicity assays were also performed between T-SN38 and T-DM1 at their respective IC50 values and the percent of cell survival determined daily from 24-96 h. Results T-SN38 was generated with a DAR of 6.97. Surprisingly, the half-life of SN38 release in acidic pH was extremely slow (t1/2=~120 h) and at the final evaluated time point (120 h) 69% of SN38 remained conjugated to trastuzumab. As anticipated, as a function of concentration T-DM1 was significantly more potent than T-SN38 (IC50=0.0013 vs 0.0832 mg/mL). However, when cytotoxicity was evaluated as a function of time T-SN38 switched to the more potent ADC at the late time points. T-SN38 killed SKOV3.ip cells 36% more effectively than T-DM1 at 96 h. Conclusions Our data from SN38 release experiments in acidic buffer suggest that pH-induced cleavage of the CL2A linker is not a contributable release mechanism of SN38 when bound to trastuzumab and is counterintuitive for what is currently described for SG. However, traceless release of hydrophobic SN38 capable of traversing cell membranes is only possible by hydrolysis of the benzyl carbonate bond. Our cytotoxicity studies over time suggest that pH-dependent release does occur. Further investigations are ongoing to more precisely determine the contribution of the carbonate bond for SN38 release and cytotoxic potency. Citation Format: Hardeep Singh, Victor Jeffrey Leyton. The CL2A-SN38 linker-payload system conjugated to trastuzumab results in improved cellular cytotoxicity over time relative to T-DM1 [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2021 Oct 7-10. Philadelphia (PA): AACR; Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P062.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
cdercder的应助被Safe采纳,获得10
刚刚
1秒前
爱卿5271完成签到,获得积分10
1秒前
1秒前
Magic麦发布了新的文献求助10
1秒前
1秒前
2秒前
2秒前
小张爱科研完成签到 ,获得积分10
2秒前
天天快乐的应助被子木采纳,获得10
2秒前
CipherSage的应助被wwwwwwww采纳,获得10
2秒前
希望天下0贩的0的应助被123采纳,获得10
3秒前
扶风阁主完成签到,获得积分10
3秒前
三月兔发布了新的文献求助10
3秒前
3秒前
爆米花的应助被桃子采纳,获得10
3秒前
明理鸿发布了新的文献求助10
3秒前
CodeCraft的应助被红颜刹朱槿采纳,获得10
4秒前
4秒前
糊涂的中恶完成签到,获得积分10
5秒前
彭于晏发布了新的文献求助10
5秒前
洛玥发布了新的文献求助10
5秒前
6秒前
6秒前
zrf发布了新的文献求助100
7秒前
李健的粉丝团团长的应助被mjq采纳,获得10
7秒前
NexusExplorer的应助被ECCE采纳,获得10
7秒前
牧木完成签到,获得积分10
7秒前
影逐光发布了新的文献求助10
7秒前
8秒前
传奇3的应助被hahage采纳,获得50
8秒前
精明梦柏完成签到,获得积分10
8秒前
8秒前
核桃发布了新的文献求助10
8秒前
勇猛的小qin完成签到 ,获得积分10
8秒前
冷酷的问梅完成签到,获得积分10
9秒前
科研通AI2S的应助被curry采纳,获得10
9秒前
自信谷冬发布了新的文献求助10
9秒前
宁灭龙发布了新的文献求助10
9秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8155737
求助须知:如何正确求助?哪些是违规求助? 9552018
关于积分的说明 21707687
捐赠科研通 7744923
什么是DOI,文献DOI怎么找? 3426177
关于科研通互助平台的介绍 2551229
邀请新用户注册赠送积分活动 2469949